Immuneering (IMRX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Immuneering

NasdaqGM•Healthcare•Biotechnology

$4.82-0.22(-0.04%)Market closed

Market Cap

$288.55M

P/B

1.5x

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

How this company scores

WeakMetricSide Score: 37/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Cash & Earnings Quality (6/25).

Profitability10/25

Growth6/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Interest easily coveredProfit converts from growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 740984.3x5y range 118.9x – 740984.3x

Currently above its 7-quarter median.

P/B · 1.5x5y range 0.9x – 6.3x

Currently near its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $288.55M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-63.15M
TTM Op. Income: $-63.47M
Q. Op. Income: $-19.00M
TTM Net Income: $-57.28M
Q. Net Income: $-17.27M
EPS: $-0.27
Shares Out.: $64.70M

$0 in TTM revenue was flat at zero YoY, reaching $0 last quarter. TTM EBITDA of $-63.15M and TTM operating income of $-63.47M show growth is flowing through to the bottom line. However, net income is negative at $57.28M — growth is not yet reaching the bottom line.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -1900040800.0%
Net Margin: -1727042700.0%

Op. margin of -1900040800.0% is down 424251400.0% YoY — costs are rising relative to revenue. Net margin at -1727042700.0% Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: 1.5x

P/S of 0.0x and P/B of 1.5x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $202.06M
Cash: $41.32M
Long-Term Debt: N/A
Book Value: $190.74M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-16.50M
TTM Free Cash Flow: $-56.99M
FCF Margin: N/A
FCF / Net Income: 1.0

TTM FCF of $-56.99M on $-16.50M in operating cash flow. The FCF / Net Income ratio of 1.0x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.